Source: Virtual Congress 2021 – Diagnostic and therapeutic advances in mesothelioma care



Rating:

Share or cite this content

Citations should be made in the following way:
J. Soerensen (Copenhagen, Denmark). Malignant mesothelioma: new treatment advances, including targeted therapies. Virtual Congress 2021 – Diagnostic and therapeutic advances in mesothelioma care

Member's Comments

No comment yet.

Related content which might interest you: New molecular-directed therapies for mesothelioma: have there been any advances? Source: International Congress 2014 – Mesothelioma: a never-ending story Year: 2014 Malignant pleural mesothelioma: new treatments, new hopes? Source: Eur Respir J , 49 (3) 1700319; DOI: 10.1183/13993003.00319-2017 Year: 2017 Malignant pleural mesothelioma: new treatment modalities Source: Annual Congress 2005 - Clinical year in review Year: 2005 Novel therapeutic strategies against malignant pleural mesothelioma by selumetinib-loaded targeted nanoparticles. Source: International Congress 2017 – Mesothelioma and malignant pleural disease Year: 2017 Systemic therapy 2 in malignant pleural mesothelioma: immuno- & targeted therapy Source: ERS Online Course 2020: Calendar sheets in malignant pleural diseases Year: 2020 The impact of multimodal treatment approaches in patients with malignant pleural mesothelioma Source: Annual Congress 2010 - Diagnostic and therapeutic problems in surgical oncology Year: 2010 Systemic treatment of malignant mesothelioma Source: Eur Respir Mon; 2009: 44: 419–434 Year: 2009 Multimodal management of malignant pleural mesothelioma: where are we today? Source: Eur Respir J 2014; 44: 754-764 Year: 2014 Novel targets and emerging therapies in MPM Source: ERS Skills course: Multi-disciplinary care in thoracic oncology Year: 2019 Combination immunotherapy in mesothelioma: managing expectations and new toxicities Source: Virtual Congress 2021 – Lung cancer grand round Year: 2021 Recent developments in the systemic treatment of malignant pleural mesothelioma: a light at the end of the tunnel! Source: International Congress 2019 – State of the art session: Thoracic oncology Year: 2019 Multimodal therapy in mesothelioma: which modalities are available and useful and how to combine them Source: International Congress 2014 – Mesothelioma: a never-ending story Year: 2014 Intrapleural photodynamic therapy for malignant pleural mesothelioma: A new dosimetry approach Source: International Congress 2016 – Mesothelioma and malignant pleural disease Year: 2016 Atypical mycobacteriosis : new drugs, new strategies Source: Annual Congress 2004 - PG11 - Multiresistant tuberculosis and atypical mycobacterial disease Year: 2004 Immunology-based therapeutic strategies in lung cancer and mesothelioma Source: International Congress 2014 – Beyond tyrosine kinase inhibition: promising new developments in molecular oncology Year: 2014 Novel approaches in metastasised non-small cell lung cancer with a special focus on modern systemic therapies Source: International Congress 2019 – State of the art session: Thoracic oncology Year: 2019 Systemic therapies: optimising the sequences of chemotherapies, targeted therapies and immunotherapies Source: International Congress 2017 – PG1 Re-defining the role of chest physicians in lung cancer: new opportunities in diagnostics and therapy Year: 2017 Update on biology and management of mesothelioma Source: Eur Respir Rev, 30 (159) 200226; 10.1183/16000617.0226-2020 Year: 2021 Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment Source: Eur Respir Rev 2016; 25: 472-486 Year: 2016